

| | EMLc | ATC codes: L01DB01 |
|--------------------------|--|--------------------|
| Indication | Lymphoid leukaemia, not elsewhere classified | ICD11 code: 2C03.3 |
| INN | Doxorubicin | |
| Medicine type | Chemical agent | |
| List type | Complementary (EML) (EMLc) | |
| Formulations | Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection ; 50 mg in vial (hydrochloride) powder for injection ; 2 mg per mL in 5 mL vial (hydrochloride) ; 2 mg per mL in 25 mL vial (hydrochloride) | |
| EML status history | First added in 2011 (TRS 965) Changed in 2015 (TRS 994) Changed in 2023 (TRS 1049) | |
| Sex | All | |
| Age | Also recommended for children | |
| Therapeutic alternatives | The recommendation is for this specific medicine | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | |
| Tags | Cancer | |
| Wikipedia | Doxorubicin  | |
| DrugBank | Doxorubicin  | |

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose forms of doxorubicin (2 mg/mL (hydrochloride) in 5 mL, 25 mL vial) to the EML and EMLc.

[Expert Committee report](#) 

